The effects of monoclonal antibody used in combination with ganciclovir (GCV) or (S)-1-[3-hydroxy-(2-phosphonylmethoxy)propyl]cytosine (HPMPC) against murine cytomegalovirus (MCMV) were determined in vitro and in vivo, in mice. The antibody and drug were added to cell cultures 24 h after MCMV adsorption so as not to affect the initial infection rate. The antibody (at 1.25-20 μg/ml) combined with GCV (0.3-5 μM) or HPMPC (0.008-0.125 μM)caused synergistic inhibition of virus yield in C127I cells. No toxic effect on cell growth in culture was observed at these antibody/drug combinations. The effects of antibody and GCV treatments were studied in MCMV-infected severe combined immunodeficient (SCID) mice. Antibody treatments (2.5 mg/kg/day) given by intraperitoneal injection every 3 days starting 24 h after virus inoculation extended survival time by 1 day relative to placebo-treated animals. Once daily, intraperitoneal treatments with GCV (25 and 50 mg/kg/day) for 7 days starting at 24 h after virus inoculation extended survival time 9-11 days. The combination of antibody plus GCV was only slightly better than GCV alone, indicating an additive interaction.